Philip Smith, MD
Ophthalmology · Minocqua, WINPI 1952351876
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,397 of the $17,503 with a category attached, or 70.8%. 33 manufacturers reported payments, led by Alcon at 54.6% of the total. Reporting peaked in 2020 at $3,720 and has fallen 51.3% since, to $1,811 in 2025. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $64.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$10K
- Glaukos Corporation$2K
- Sight Sciences, Inc.$831
- AbbVie$699
- Rxsight Inc$480
- Bausch & Lomb, A Division Of Bausch Health US, LLC$456
- plus $3K from 27 others
What the payments were for
- Consulting fees$2,22013%
- Speaking & faculty fees$2,83916%
- Food & beverage$12,39771%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 91 | $9,551 |
| Glaukos Corporation | 28 | $2,404 |
| Sight Sciences, Inc. | 14 | $831 |
| AbbVie(2 entities) | 17 | $699 |
| Rxsight Inc | 7 | $480 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 39 | $456 |
| Biotissue Holdings Inc. | 9 | $368 |
| Alcon Research LLC | 1 | $350 |
| Ivantis, Inc | 3 | $304 |
| Beaver-visitec International, Inc. | 4 | $240 |
| Novartis | 6 | $233 |
| Aerie Pharmaceuticals, Inc. | 4 | $213 |
| Dompe US, Inc. | 5 | $197 |
| Oyster Point Pharma, Inc. | 4 | $172 |
| Carl Zeiss Meditec USA, Inc. | 1 | $165 |
| Astellas Pharma US Inc | 3 | $92 |
| Bausch & Lomb Americas Inc. | 3 | $90 |
| Apellis Pharmaceuticals, Inc. | 4 | $84 |
| Ocular Therapeutix, Inc. | 3 | $84 |
| Sun Pharmaceutical Industries Inc. | 4 | $81 |
| Omeros Corporation | 2 | $62 |
| Kala Pharmaceuticals, Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Genentech USA, Inc. | 1 | $47 |
| NEW World Medical,inc. | 4 | $30 |
| The Cameron-ehlen Group, Inc. | 2 | $29 |
| Tarsus Pharmaceuticals, Inc. | 1 | $22 |
| Akorn, Inc. | 1 | $21 |
| Thea Pharma Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Harrow Eye, LLC | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof IQ PanOptix$2,800
- AcrySof$1,355
- Clareon$645
- AcrySof IQ PanOptix UV IOL$492
- OMNI(R) SURGICAL SYSTEM (US)$421
- iStent inject Trabecular Micro-Bypass Stent System$342
- Hydrus$276
- ARGOS$265
- XEN GLAUCOMA TREATMENT SYSTEM$252
- iDoseTR$191
- SION SURGICAL INSTRUMENT$171
- iStent Inject Trabecular Micro-Bypass System$169
- iPRIME Viscodelivery System$169
- ARTEVO 800$165
- Rhopressa$146
- Rocklatan$146
- Prokera$145
- AmnioGraft$145
- LenSx$136
- iDose$132
How this compares
$17,503 in reported general payments places this provider in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 342 | $14,613 |
| ProlensaBromfenac Sodium | 21 | $7,328 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $4,734 |
| Ketorolac Tromethamine | 244 | $4,496 |
| Bromfenac Sodium | 13 | $2,284 |
| Ofloxacin | 129 | $1,368 |
| Ciprofloxacin Hcl | 71 | $805 |
| Latanoprost | 47 | $682 |
| Timolol Maleate | 21 | $244 |
| Dorzolamide Hcl | 12 | $233 |
| ValacyclovirValacyclovir Hcl | 11 | $199 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $177 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $456 | $7,32821 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $213 | $4,73414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Minocqua
- Inder SinghRacine$2.5M
- Deepak SambharaWausau$388K
- John VukichWauwatosa$356K
- Eugene EldridgeKenosha$294K
- Michael ShapiroMadison$71K
- Douglas SalmAppleton$38K
- Julia AgapovMadison$26K
- Thomas HarveyChippewa Falls$23K
- Michael VrabecAppleton$20K
- Syed Shahla Crosse$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.